{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"Complete response (CR): complete disappearance of all target lesions, confirmed by repeat assessments at no less than 4 weeks after the criteria for response are first met. Partial response (PR): at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. This must be confirmed by repeat assessment at no less than 4 weeks after the criteria for response are first met. Stable Disease (SD): neither sufficient decrease to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started.","groups":[{"description":"The investigational drug used in this study is pasireotide long acting release (LAR) 60 mg.\n\nPasireotide Long Acting Release (LAR): Pasireotide will be administered as an intramuscular injection at the beginning of every cycle which is defined as 28 days (+/- 3 days). Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Pasireotide LAR Treatment"}],"paramType":"NUMBER","populationDescription":"evaluable participants","reportingStatus":"POSTED","timeFrame":"Up to 48 months","title":"Overall Radiographic Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}